Non-Hallucinogenic Psychedelic Treatment For Anxiety And Depression In Pre-Clinical Models Enveric Biosciences Breakthrough Research
| ATRXDelisted Stock | USD 0.72 0.00 0.00% |
Slightly above 56% of Adhera Therapeutics' investor base is looking to short. The analysis of overall sentiment of trading Adhera Therapeutics pink sheet suggests that many investors are alarmed at this time. Adhera Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Adhera Therapeutics' earnings reports, geopolitical events, and overall market trends.
Adhera |
Psychedelics biotech company Enveric Biosciences has presented research highlighting the companys lead compound, EB-003 at the 7th Neuropsychiatric Drug Summit. The conference is being held at the Hilton Boston Back Bay in Boston, Massachusetts on Sept. 24-26, 2024. EB-003 is a neuropathogenic and non-hallucinogenic N, N-Dimethyltryptamine analog drug candidate that showed beneficial outcomes in preclinical models of anxiety and depression. The move follows the companys July announcement of positive pre-clinical results of its EB-003 drug candidate to be delivered via oral administration. The results indicated that oral administration of EB-003 provides significant brain exposure in rodent models at potential therapeutic doses.
Read at benzinga.com
 |
Adhera Therapeutics Fundamental Analysis
We analyze Adhera Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Adhera Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Adhera Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Valuation
Current Valuation Comparative Analysis
Adhera Therapeutics is currently under evaluation in current valuation category among its peers. Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Adhera Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Adhera Therapeutics pink sheet to make a market-neutral strategy. Peer analysis of Adhera Therapeutics could also be used in its relative valuation, which is a method of valuing Adhera Therapeutics by comparing valuation metrics with similar companies.
Peers
Adhera Therapeutics Related Equities
| ENVB | Enveric Biosciences | 2.56 | ||||
| ASCLF | Ascletis Pharma | 0.00 |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Other Consideration for investing in Adhera Pink Sheet
If you are still planning to invest in Adhera Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Adhera Therapeutics' history and understand the potential risks before investing.
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |